Su454 IMMUNOMODULATORS ARE COMMONLY USED AS CONCOMITANT THERAPY WITH VEDOLIZUMAB OR USTEKINUMAB: TARGET-IBD REAL WORLD COHORTMegan Lutz,Freddy Caldera, Katie Schroeder,Derek Gazis,Janet S. Hildebrand,Julie M. Crawford,Millie D. Long,Edward L. BarnesGastroenterology(2021)引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要